Inter-assay variability in anti–JC virus testing for natalizumab: A Spanish cohort
- 20 January 2026
- journal article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 107, 107023
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Stratify and ImmunoWELL JCV tests performances in a real-world multiple sclerosis cohort: possible clinical implications of biosimilar Natalizumab useJournal of Neurology, 2025
- Diagnostic uncertainty in the era of biosimilar natalizumab—The case for harmonizing anti-JCV antibody testingMultiple Sclerosis Journal, 2025
- Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?Multiple Sclerosis Journal, 2025
- A comparison of JC virus assay performance provided with originator and biosimilar natalizumabMultiple Sclerosis Journal, 2025
- Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple SclerosisJAMA Neurology, 2023
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studiesThe Lancet Neurology, 2017